FDA approved bosutinib tablets (Bosulif, Pfizer, Inc.) for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior therapy. September 4, 2012. More Information:http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm
Comments
Post a Comment